| Cell line name |
HUH7-R-LUC |
|---|
| Accession |
CVCL_B7TJ |
|---|
| Resource Identification Initiative |
To cite this cell line use: HUH7-R-LUC (RRID:CVCL_B7TJ) |
|---|
| Comments |
Population: Japanese.
Selected for resistance to: ChEBI; CHEBI_50924; Sorafenib (Nexavar).
Genetic integration: Method=Transfection/transduction; Gene=FPbase; R9NL8; eGFP (Note=Enhanced GFP).
Genetic integration: Method=Transfection/transduction; Gene=UniProtKB; P08659; Photinus pyralis firefly-type luciferase.
Derived from site: In situ; Liver; UBERON=UBERON_0002107. |
|---|
| Sequence variations |
- Mutation; HGNC; HGNC:6307; KDR; Simple; p.Gln472His (c.1416A>T); ClinVar=VCV000134603; Zygosity=Homozygous (from parent cell line).
- Mutation; HGNC; HGNC:20932; POLD3; Simple; p.Lys109Arg (c.326A>G) (p.Lys70Arg, c.209A>G); Zygosity=Unspecified (from parent cell line).
- Mutation; HGNC; HGNC:11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line).
- Mutation; HGNC; HGNC:11998; TP53; Simple; p.Tyr220Cys (c.659A>G); ClinVar=VCV000127819; Zygosity=Homozygous (from parent cell line).
|
|---|
| Disease |
Adult hepatocellular carcinoma (NCIt: C7956)
Adult hepatocellular carcinoma (ORDO: Orphanet_210159) |
|---|
| Species of origin |
Homo sapiens (Human)
(NCBI Taxonomy: 9606) |
|---|
| Hierarchy |
Parent: CVCL_B7TI (HUH7-R) |
|---|
| Sex of cell |
Male |
|---|
| Age at sampling |
57Y |
|---|
| Category |
Cancer cell line |
|---|
| Publications | DOI=10.5282/edoc.26548
Martina Messner;
Sorafenib resistance of hepatocellular carcinoma: antibiotics second- line to sorafenib therapy inhibit mitochondrial biogenesis and prevent tumor growth resumption.
Thesis PhD (2020); Ludwig Maximilians University of Munich; Munich; Germany PubMed=32652772; DOI=10.1096/fj.202001128R
Martina Messner, Sabine Schmitt, Maximilian Alexander Ardelt, Thomas Frohlich, Martin Muller, Helmut Pein, Petra Huber-Cantonati, Carina Ortler, Lars M. Koenig, Lena Zobel, Andreas Koeberle ...Show all 18 authors... , Georg J. Arnold, Simon Rothenfusser, Alexandra K. Kiemer, Alexander L. Gerbes, Hans Zischka, Angelika M. Vollmar, Johanna Pachmayr; Show fewer authors
Metabolic implication of tigecycline as an efficacious second-line treatment for sorafenib-resistant hepatocellular carcinoma.
FASEB J. 34:11860-11882(2020) |
|---|
| Cross-references |
|---|
| Cell line databases/resources |
cancercelllines; CVCL_B7TJ
|
|---|
| Encyclopedic resources |
Wikidata; Q112929800
|
|---|
| Entry history |
|---|
| Entry creation | 23-Jun-2022 |
|---|
| Last entry update | 14-Aug-2025 |
|---|
| Version number | 10 |
|---|
